# Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases

> **NCT06775912** · EARLY_PHASE1 · RECRUITING · sponsor: **Nanjing Bioheng Biotech Co., Ltd.** · enrollment: 18 (estimated)

## Conditions studied

- SLE
- Systemic Sclerosis
- IIM
- NMOSD
- MS
- MG
- ANCA Associated Vasculitis (AAV)

## Interventions

- **DRUG:** RD06-05 CART Cell Injection

## Key facts

- **NCT ID:** NCT06775912
- **Lead sponsor:** Nanjing Bioheng Biotech Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-01-03
- **Primary completion:** 2027-01-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 18 (ESTIMATED)
- **Last updated:** 2026-02-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06775912

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06775912, "Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT06775912. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*